Satsuma Pharma rounds up $80M to give its migraine treatment another shot
Satsuma Pharmaceuticals executives say they now understand why their intranasal migraine treatment failed a pivotal test. But even with a new Phase 3 plan, the company is behind a competitor that could launch its intranasal migraine treatment later this year.